Peter Davies PhD, is the director of the Litwin-Zucker Research Center for The Study of Alzheimer’s Disease and Memory Disorders associated with The Feinstein Institute for Medical Research in Manhasset, NY.
Peter Davies received his B.Sc. and Ph.D. both in Biochemistry from the University of Leeds. He was a post-doctoral fellow at the University of Edinburgh, Scotland before joining the staff of the Medical Research Council Brain Metabolism Unit in Edinburgh in 1974, where he began his research on Alzheimer’s disease.
In 1977, Davies moved to Albert Einstein College of Medicine, after which he came to his current position.
For more than 35 years, Davies’ research has been focused on the biochemistry of Alzheimer’s disease. His early work was instrumental in the development of the currently approved drugs for Alzheimer’s disease: Aricept, Exelon, and Razodyne. Davies is interested in the pathway of Alzheimer’s disease and has said that the disease may be a process of cell cycle division gone wild. Davies and his collaborators have already identified a marker in cerebrospinal fluid (CSF) that can distinguish Alzheimer’s disease from normal aging, as well as discriminate between Alzheimer’s and other forms of dementia.
The overall goal of Davies’ research is to develop treatments to slow or halt the progression of Alzheimer’s disease.
Peter Davies has received multiple awards, the last one being the 2015 Potamkin Award for research in Pick‘s, Alzheimer’s, and related diseases